Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
09/10/2026 13:13
BRIEF-Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value Oct 9 (Reuters) - Atossa Therapeutics Inc ATOS.O:
ATOSSA THERAPEUTICS EXECUTES CONTINGENT VALUE RIGHTS AGREEMENT PROVIDING SHAREHOLDERS PARTICIPATION IN POTENTIAL PRIORITY REVIEW VOUCHER VALUE
ATOSSA THERAPEUTICS - DECLARES ONE STAPLED CVR PER SHARE AS OF OCTOBER 19, 2026
ATOSSA THERAPEUTICS - CVR HOLDERS ENTITLED TO 25% OF NET PROCEEDS, $50 MILLION AGGREGATE CAP
Source text: ID:nPn7Qk7Bqa
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary